MedTrace Logo

VR Assessment for Alcohol Related Brain Damage

NCT03826238 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2021-05-03

No results posted yet for this study

Summary

Pilot study where 10 alcohol-related brain damage (ARBD) patients will undergo a 30-minutes-long cognitive assessment session using the Validation Gate task to evaluate usability of this tool in Alcohol Use Disorder patients. Resting-state EEG of ARBD patients will also be recorded and compared to the ones of age-matched healthy people in order to preliminary explore the existence of possible EEG biomarkers of ARBD.

Conditions

  • Alcohol-Related Disorders

Interventions

DIAGNOSTIC_TEST

Validation Gate task

The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a "jump". The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Institute for Bioengineering of Catalonia

    collaborator OTHER

  • Universitat Pompeu Fabra

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-11-30
Completion
2022-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03826238 on ClinicalTrials.gov